Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Year of publication
- 2021 (18) (remove)
Document Type
- Journal article (9)
- Doctoral Thesis (9)
Keywords
- DNA damage (2)
- DNA repair (2)
- Herzhypertrophie (2)
- biomedicine, general (2)
- cAMP (2)
- environmental health (2)
- occupational medicine/industrial medicine (2)
- pharmacology/toxicology (2)
- 3R (1)
- Bioluminescence resonance energy transfer (1)
- Biomarker (1)
- CaMKII (1)
- Celecoxib (1)
- Cell death and comet assay (1)
- Cyclo-AMP (1)
- DNS-Schädigung (1)
- Dimerisierung (1)
- ERK-Kaskade (1)
- ERK-cascade (1)
- ERK1/2 (1)
- FRET (1)
- Förster Resonanz Energie Transfer (1)
- G-Protein gekoppelte Rezeptoren (1)
- G-protein-coupled receptors (1)
- GPCR (1)
- Genotoxicity (1)
- Genotoxizität (1)
- High-thropughput screening (1)
- Hochdurchsatz-Screening (1)
- Huh6 (1)
- Hypertonie (1)
- In-silico Modell (1)
- Insulin (1)
- Interferenz (1)
- Kleinkern (1)
- Kognitive Beeinträchtigung (1)
- Lasiocarpin (1)
- Lebendzellmikroskopie (1)
- MAP-Kinase (1)
- Micronucleus (1)
- Mikrokern (1)
- Mundschleimhautzellen (1)
- Mutagenität (1)
- Oxidativer Stress (1)
- PDE (1)
- PDE2 (1)
- Phosphodiesterase (1)
- Pyrrolizidinalkaloide (1)
- Receptor dynamics (1)
- SCN5a (1)
- Senecionin (1)
- Seneciphyllin (1)
- Systembiologie (1)
- Thebain (1)
- alternative methods (1)
- arrhythmia (1)
- biomarker of exposure (1)
- blood samples (1)
- cardiac hypertrophy (1)
- comet assay (1)
- compartments (1)
- conduction disease (1)
- danio rerio (1)
- familial DCM (1)
- genotoxicity (1)
- glucuronide (1)
- heart failure (1)
- huh6 (1)
- human biomonitoring (1)
- in-silico model (1)
- lasiocarpine (1)
- mercapturic acid (1)
- mutation triggers (1)
- mycotoxin (1)
- ochratoxin A (1)
- organ toxicity (1)
- phosphorylation (1)
- senecionine (1)
- seneciphylline (1)
- transgenic animals (1)
- γ-H2AX (1)
Institute
- Institut für Pharmakologie und Toxikologie (18) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 965286 (1)
- QLK1-2001-01614 (1)
ERK1/2 are known key players in the pathophysiology of heart failure, but the members of the ERK cascade, in particular Raf1, can also protect the heart from cell death and ischemic injury. An additional autophosphorylation (ERK1 at Thr208, ERK2 at Thr188) empowers ERK1/2 translocation to the nucleus and phosphorylation of nuclear targets which take part in the development of cardiac hypertrophy. Thereby, targeting this additional phosphorylation is a promising pharmacological approach.
In this thesis, an in silico model of ERK cascade in the cardiomyocyte is introduced. The model is a semi-quantitive model and its behavior was tested with different softwares (SQUAD and CellNetAnalyzer). Different phosphorylation states of ERK1/2 as well as different stimuli can be reproduced. The different types of stimuli include hypertrophic as well as non-hypertrophic stimuli. With the introduced in-silico model time courses and synergistic as well as antagonistic receptor stimuli combinations can be predicted. The simulated time courses were experimentally validated. SQUAD was mainly used to make predictions about time courses and thresholds, whereas CNA was used to analyze steady states and feedback loops.
Furthermore, new targets of ERK1/2 which partially contribute, also in the formation of cardiac hypertrophy, were identified and the most promising of them were illuminated. Important further targets are Caspase 8, GAB2, Mxi-2, SMAD2, FHL2 and SPIN90.
Cardiomyocyte gene expression data sets were analyzed to verify involved components and to find further significantly altered genes after induced hypertrophy with TAC (transverse aortic constriction). Changes in the ultrastructure of the cardiomyocyte are the final result of induced hypertrophy.